Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.72 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.72 |
| ▸ | TSHR | P16473 | 5/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.67 |
| ▸ | MTOR | P42345 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Colterol SCHEMBL3220142 | 1.00 | ADRB2 (0.72) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| Colterol SCHEMBL3207818 | 1.00 | ADRB2 (0.72) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| Colterol SCHEMBL10604477 | 0.92 | ADRB2 (0.63) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| Colterol SCHEMBL636005 | 0.92 | PMP22 (0.71) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL6711726 | 0.87 | ADRB2 (0.68) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL30438779 | 0.87 | ADRB2 (0.68) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| Terbutaline SCHEMBL1668880 | 0.86 | ADRB2 (0.67) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL20819658 | 0.85 | ADRB1 (0.69) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL20833681 | 0.85 | ADRB1 (0.69) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL11278982 | 0.85 | ADRB2 (0.62) | ADRB2ADRB1TSHRHIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 738 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS, INC. | 2026-01-29 | — | — | US | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | claimed |
| US-20240139224-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | AMERICAN ENTERTAINMENT PROPERTIES CORP., AS LENDER | 2024-05-02 | — | — | US | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | claimed |
| US-20210338603-A1 | COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | ATROGI AB (SE) | 2021-11-04 | — | — | US | claimed |
| US-20210161932-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS LLC | 2021-06-03 | — | — | US | claimed |
| US-20200315993-A1 | COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | ATROGI AB (SE) | 2020-10-08 | — | — | US | claimed |
| US-5684018-A | Acyloxyisopropyl carbamates as prodrugs for amine drugs | MERCK & CO., INC. (US) | 1997-11-04 | — | — | US | claimed |
| WO-1997019680-A1 | THERAPEUTICAL USE OF BETA-MIMETIC AGENTS FOR THE TRANSMUCOSAL TREATMENT OF DYSMENORRHOEA | BOYER CHRISTOPHE (FR) | 1997-06-05 | — | — | WO | claimed |
| WO-1996018605-A1 | ACYLOXYISOPROPYL CARBAMATES AS PRODRUGS FOR AMINE DRUGS | MERCK & CO., INC. (US) | 1996-06-20 | — | — | WO | claimed |
| EP-0248150-B1 | GASTROPROTECTIVE PROCESS AND COMPOSITIONS | Bristol-Myers Squibb Company (US) | 1992-07-15 | — | — | EP | claimed |
| US-5043358-A | Administering beta adrenergic agonists with non-steroidal anti-inflammatory drugs | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-08-27 | — | — | US | claimed |
| US-4965065-A | ADMINISTERING NONSTEROIDAL ANTIINFLAMMATORY AGENTS WITH BETA ADRENERGIC AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-10-23 | — | — | US | claimed |
| EP-0036426-B1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES | INTERx RESEARCH CORPORATION (US) | 1986-04-23 | — | — | EP | claimed |
| US-4313956-A | Novel sypathomimetic amine prodrugs | INTERX RESEARCH CORP. (US) | 1982-02-02 | — | — | US | claimed |
| US-4275219-A | Novel process and intermediates useful in the preparation of sympathomimetic amines | INTERX RESEARCH CORPORATION (US) | 1981-06-23 | — | — | US | claimed |
| US-4153677-A | MICROENCAPSULATED BRONCHODILATOR AGENT, ETHYL CELLULOSE FILM | STERLING DRUG INC. (US) | 1979-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | CYP21A2, HSD11B2, CA2 | ADRB2 229/4885ADRB1 237/4885TSHR 1682/4885 |
| US-20200315993-A1 | COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | ADRB2, ADRB3, ADRA2C | ADRB2 1/4885ADRB1 5/4885TSHR 102/4885 |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | ADRB2 2/4885ADRB1 3/4885TSHR 2692/4885 |
| US-20210161932-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | CA4, CA9, CA7 | ADRB2 543/4885ADRB1 464/4885TSHR 2362/4885 |
| US-20240139224-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | CA4, CA9, CA7 | ADRB2 543/4885ADRB1 464/4885TSHR 2362/4885 |
| US-20210338603-A1 | COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | ADRB2, ADRB3, ADRA2C | ADRB2 1/4885ADRB1 5/4885TSHR 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.